• President Trump's executive order aims to align Medicare drug prices with the lowest international rates.
  • The policy specifically targets medications administered in doctors' offices, potentially cutting costs by 30-80%.
  • Implementation faces hurdles, including potential pushback from pharmaceutical companies and questions about enforcement.

Trump Revives Drug Pricing Policy

President Trump is set to sign an executive order today implementing a "Most Favored Nation" policy for prescription drug pricing, directing Medicare to pay no more than the lowest prices offered in other countries. The move, announced on his social media platform, targets medications like cancer infusions and other injectables covered by Medicare, with Trump claiming it could slash prices by 30-80%.

This marks Trump's second attempt at the policy after failing to enact it during his first term. Health and Human Services Secretary Robert F. Kennedy Jr. had telegraphed the move, citing drugs like Ozempic as examples where U.S. prices exceed those abroad. "We're ensuring America is treated fairly," Trump said, predicting "trillions" in savings—a figure some analysts view as inflated.

Limited Scope, Big Implications

The order's impact would be confined to Medicare Part B drugs administered in clinical settings, leaving retail pharmacy purchases unaffected. While the Republican-controlled Congress has generally backed Trump's healthcare agenda, the policy's legality via executive action remains untested. Pharmaceutical companies could theoretically adjust international pricing to maintain margins, though such moves might provoke regulatory scrutiny.

Coming a week after another pharma-focused order streamlining domestic manufacturing approvals, the administration appears to be making drug costs a priority. As one healthcare lobbyist noted anonymously, "This puts immediate pressure on biologics and specialty meds—the big-ticket items where price differentials are starkest." The HHS declined to comment on enforcement timelines ahead of the signing ceremony.